ArticleFrontiers in pharmacology2025
Acetyl-11-keto-beta-boswellic acid ameliorates monosodium iodoacetate-induced osteoarthritis in rats: implications of HMGB1/TLR4/NF-κB and Nrf2/HO-1.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is a prevalent joint disorder marked by chronic inflammation and degradation of cartilage. The shielding effect of 3-O-acetyl-11-keto-β-boswellic acid (AKBA) has been confirmed in many inflammatory disorders. However, the full underlying mechanistic perspective of AKBA against OA remains unexplored. Thus, the objective of this work is to identify additional unexamined modulatory signals of AKBA against monosodium iodoacetate (MIA)-induced OA and the early prevention of irreversible cartilage damage. Methods: Male Wistar rats were allotted into three groups (n = 9): sham, MIA-OA, and MIA + AKBA250. Three mg of MIA was injected intra-articularly into the right knee joints of rats to induce OA on day 0. All treatments were given orally, daily, starting on the 3rd day after MIA injection and continuing until the 14th day of the experiment. Results: AKBA250 treatment alleviated edema completely, achieving nearly basal records of the right knee diameter. AKBA250 treatment enhanced macroscopic and microscopic findings and normalized the modified Mankin and OARSI scoring system. Moreover, AKBA restored cartilage matrix homeostasis by suppressing the catabolic enzyme matrix metalloproteinase-13 (MMP-13), upregulating tissue inhibitor of metalloproteinase-1 (TIMP-1) and the chondrogenic marker SRY-box transcription factor 9 (SOX9), and reducing the serum level of the cartilage degradation biomarker C-telopeptide of type II collagen (CTX-II). The contents of high-mobility group box 1 (HMGB1), toll-like receptor 4 (TLR4), nuclear factor-kappa B (NF-κB), and tumor necrosis factor-α (TNF-α) were substantially suppressed in the AKBA250-treated group. AKBA250 significantly boosted the nuclear factor erythroid-2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) levels and restored the oxidant/antioxidant equilibrium disrupted by MIA. In addition, AKBA250 prominently curbed the protein expression of p-RIPK1, p-RIPK3, and p-MLKL. Furthermore, AKBA250 exhibited downregulation of miR-34a-5p and miR-146a expressions. Conclusion: Together, AKBA demonstrated a protective function in OA by inhibiting inflammatory signaling through the HMGB1/TLR4/NF-κB pathway, augmenting the cytoprotective Nrf2/HO-1 pathway, and regulating necroptosis signaling cascades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.